Featured News
Shifting Technology Platforms
Developing new research platforms as an alternative to animals
For over 75 years, Charles River has invested in and embraced innovations in biopharmaceutical research. We are deeply committed to initiatives that enhance the welfare and reduce the impact on animals, which are embedded in the 3Rs principles of replacement, reduction, and refinement. We’re focused on the continuous development and responsible expansion of animal alternatives through in vitro platforms and digital technologies while maintaining a focus on patient safety.
We are living in unprecedented times as life science players embrace advanced molecular biology, synthetic biology, human tissue engineering and AI to drive how we discover, develop and quality assure new therapeutics; these scientific pillars provide a launch pad for Charles Rivers approach to reducing animal usage over the next decade.”
Julie Frearson, SVP Chief Scientific Officer, Corporate Development
Learn About Our Progress
Endosafe® Trillium™ Recombinant Cascade Reagent (rCR), our animal-free recombinant for endotoxin detection, was developed with scientific rigor and the highest quality to ensure patient safety and does not use horseshoe crab (HSC) blood for source materials.
PathogenBinder™ is a novel technology impacting sentinel-free health monitoring for all vivaria globally through a soiled-bedding sampling system, combined with our proprietary PCR test for optimized detection of rodent pathogens. This methodology reduces the need for one million sentinel rodents annually.
Next Generation Sequencing (NGS) services available through a partnership with PathoQuest provide a powerful alternative to animal testing and compliance assistance in the detection of viral contaminants in biologics.
Retrogenix® Cell Microarray Technology supports IND-enabling specificity testing of multiple biologics modalities (antibodies, CAR constructs, viral vectors, etc.) and provides in vitro libraries to de-risk in vivo studies across species.